Physician profile
Rajbinder Gill
NPI 1487688164
$1,976.01
in general payments reported to CMS, 2019-2025
30 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $11.39 · 2021: $43.26 · 2022: $45.44 · 2023: $299 · 2024: $717 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $211.93 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $202.21 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $133.82 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.20 | 2024 | |
| Corcept Therapeutics | $124.79 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $110.72 | 2019-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $104.18 | 2024-2025 | Voquezna |
| Abbvie INC. | $96.94 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $92.07 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $90.31 | 2019-2024 | Eliquis |
| Glaxosmithkline, LLC. | $81.75 | 2019-2023 | Arexvy, Shingrix |
| Ironwood Pharmaceuticals, INC | $73.80 | 2019 | |
| Exact Sciences Corporation | $69.86 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $57.69 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $46.62 | 2024 | Rebyota |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $46.03 | 2025 | Tremfya |
| Agios Pharmaceuticals, INC. | $36.26 | 2025 | Pyrukynd |
| Amarin Pharma, INC. | $36.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.25 | 2019 | |
| Abbott Laboratories | $23.93 | 2024 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $23.80 | 2024 | Heplisav-B |
| Grifols USA, LLC | $20.56 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.51 | 2019 | |
| Recordati_rare_diseases_inc. | $20.46 | 2025 | Isturisa |
| Alexion Pharmaceuticals, INC. | $18.99 | 2025 | Strensiq |
| Ucb, INC. | $18.03 | 2024 | Bimzelx |
| Astellas Pharma US INC | $16.98 | 2024 | Veozah |
| Allergan, INC. | $16.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.83 | 2019 | |
| Merck Sharp & Dohme LLC | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajbinder Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.